Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease-Reference-Cited by-同舟云学术

Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease

Published:2019 Issue: Volume:39 Page:100002
ISSN:1567-5688
Container-title:Atherosclerosis Supplements
language:en
Short-container-title:Atherosclerosis Supplements

Author:

Catapano Alberico L.,Tokgözoğlu Lale,Mello e Silva Alberto,Bruckert Eric

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,General Medicine,Internal Medicine

Reference41 articles.

1. ESC/EAS guidelines for the management of dyslipidaemias;Catapano;Eur. Heart J.,2016

2. 2016 European Guidelines on cardiovascular disease prevention in clinical practice

3. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials;Boekholdt;J. Am. Coll. Cardiol.,2014

4. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Stone;Circulation,2013

5. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis;Law;BMJ,2003

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Far-infrared irradiation increases the uptake of LDL cholesterol by downregulating PCSK9 through the activation of TRPV4 calcium channels in HepG2 cells;Biochemical and Biophysical Research Communications;2024-09

2. Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study;Clínica e Investigación en Arteriosclerosis;2023-11

3. Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study;Clínica e Investigación en Arteriosclerosis (English Edition);2023-11

4. Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study;The Lancet Regional Health - Europe;2023-08

5. Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study;Wiener klinische Wochenschrift;2023-07-31